{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:34:00Z","timestamp":1795019640915,"version":"4.10.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HR21C1003"],"award-info":[{"award-number":["HR21C1003"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003653","name":"Korea National Institute of Health","doi-asserted-by":"publisher","award":["HR22C1734"],"award-info":[{"award-number":["HR22C1734"]}],"id":[{"id":"10.13039\/501100003653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1H1A2093189"],"award-info":[{"award-number":["NRF-2022R1H1A2093189"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C2092422"],"award-info":[{"award-number":["NRF-2022R1A2C2092422"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022M3A9G101451421"],"award-info":[{"award-number":["NRF-2022M3A9G101451421"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1C1C1009619"],"award-info":[{"award-number":["NRF-2021R1C1C1009619"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer cases and related deaths. The purpose of this study was to assess the diagnostic value of splicing factor 3b subunit 4 (SF3B4) as a novel non-invasive biomarker for HCC and determine the association between <jats:italic>SF3B4<\/jats:italic> expression and immune cell infiltration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An enzyme-linked immunosorbent assay (ELISA) was used to detect SF3B4 levels in plasma samples obtained from healthy controls (HCs) and patients with chronic hepatitis, liver cirrhosis, and HCC. The expression levels of autoantibodies that detect SF3B4 in the plasma samples of each group of patients were measured. Small extracellular vesicles (EVs) were isolated from patient sera, and the expression levels of EV-<jats:italic>SF3B4<\/jats:italic> were measured using quantitative reverse transcription PCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ELISA results confirmed that the expression levels of SF3B4 proteins and autoantibodies in the plasma of patients with HCC were higher than those in HCs. However, their diagnostic performance was not better than that of alpha-fetoprotein (AFP). The mRNA expression of <jats:italic>SF3B4<\/jats:italic> in serum EV increased but not in the buffy coat or serum of patients with HCC. Serum EV-<jats:italic>SF3B4<\/jats:italic> displayed better diagnostic power than AFP for all stages of HCC (AUC\u2009=\u20090.968 vs. 0.816), including early-stage HCC (AUC\u2009=\u20090.960 vs. 0.842), and this was consistent in the external cohort. Single-cell RNA sequencing indicated that <jats:italic>SF3B4<\/jats:italic> expression was correlated with myeloid-derived suppressor cells. The Tumor Immune Estimation Resource database reconfirmed the correlation between <jats:italic>SF3B4<\/jats:italic> expression and immune cell infiltration in HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SF3B4 may be associated with tumor immune infiltration in HCC, and EV-<jats:italic>SF3B4<\/jats:italic> shows potential as a novel non-invasive diagnostic biomarker of HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02867-y","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:01:43Z","timestamp":1698631303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma"],"prefix":"10.1186","volume":"42","author":[{"given":"Ju A","family":"Son","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyang","family":"Weon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geum Ok","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ri","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Gyeong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Youn","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Woo","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1896","authenticated-orcid":false,"given":"Soon Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2867_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/liv.15251","volume":"42","author":"CH Zhang","year":"2022","unstructured":"Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42:2029\u201341.","journal-title":"Liver Int"},{"key":"2867_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"2867_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"2867_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362.","journal-title":"Lancet"},{"key":"2867_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","volume":"30","author":"A Singal","year":"2009","unstructured":"Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with Cirrhosis. Aliment Pharmacol Ther. 2009;30:37\u201347.","journal-title":"Aliment Pharmacol Ther"},{"key":"2867_CR7","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1053\/jhep.2003.50195","volume":"37","author":"JA Marrero","year":"2003","unstructured":"Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114\u201321.","journal-title":"Hepatology"},{"key":"2867_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.31165","volume":"73","author":"JC Ahn","year":"2021","unstructured":"Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73:422\u201336.","journal-title":"Hepatology"},{"key":"2867_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jhep.2011.11.026","volume":"56","author":"F Borel","year":"2012","unstructured":"Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012;56:1371\u201383.","journal-title":"J Hepatol"},{"key":"2867_CR10","doi-asserted-by":"crossref","unstructured":"Kisiel JB, Dukek BA, R VSRK, Ghoz HM, Yab TC, Berger CK, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology. 2019;69:1180-92.","DOI":"10.1002\/hep.30244"},{"key":"2867_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.18632\/oncoscience.446","volume":"5","author":"J von Felden","year":"2018","unstructured":"von Felden J, Craig AJ, Villanueva A. Role of circulating Tumor DNA to help decision-making in hepatocellular carcinoma. Oncoscience. 2018;5:209\u201311.","journal-title":"Oncoscience"},{"key":"2867_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cgh.2006.12.005","volume":"5","author":"A Leerapun","year":"2007","unstructured":"Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007;5:394\u2013402 (quiz 267).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2867_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/hep.29606","volume":"67","author":"Q Shen","year":"2018","unstructured":"Shen Q, Eun JW, Lee K, Kim HS, Yang HD, Kim SY, et al. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma. Hepatology. 2018;67:1360\u201377.","journal-title":"Hepatology"},{"key":"2867_CR14","doi-asserted-by":"publisher","first-page":"11157","DOI":"10.18632\/aging.102518","volume":"11","author":"Y Lin","year":"2019","unstructured":"Lin Y, Liang R, Ye J, Li Q, Liu Z, Gao X, et al. A twenty gene-based gene set variation score reflects the pathological progression from Cirrhosis to hepatocellular carcinoma. Aging. 2019;11:11157\u201369.","journal-title":"Aging"},{"key":"2867_CR15","first-page":"123","volume":"32","author":"L Yan","year":"2021","unstructured":"Yan L, Yang X, Yang X, Yuan X, Wei L, Si Y, et al. The role of splicing factor SF3B4 in congenital diseases and tumors. Discov Med. 2021;32:123\u201332.","journal-title":"Discov Med"},{"key":"2867_CR16","doi-asserted-by":"publisher","first-page":"101042831769591","DOI":"10.1177\/1010428317695913","volume":"39","author":"W Zhou","year":"2017","unstructured":"Zhou W, Ma N, Jiang H, Rong Y, Deng Y, Feng Y, et al. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Tumour Biol. 2017;39:1010428317695913.","journal-title":"Tumour Biol"},{"key":"2867_CR17","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.21873\/anticanres.14272","volume":"40","author":"S Kidogami","year":"2020","unstructured":"Kidogami S, Iguchi T, Sato K, Yoshikawa Y, Hu Q, Nambara S, et al. SF3B4 plays an oncogenic role in esophageal squamous cell carcinoma. Anticancer Res. 2020;40:2941\u20136.","journal-title":"Anticancer Res"},{"key":"2867_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41419-022-04630-1","volume":"13","author":"Y Diao","year":"2022","unstructured":"Diao Y, Li Y, Wang Z, Wang S, Li P, Kong B. SF3B4 promotes Ovarian cancer progression by regulating alternative splicing of RAD52. Cell Death Dis. 2022;13:179.","journal-title":"Cell Death Dis"},{"key":"2867_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cancergencyto.2007.01.011","volume":"175","author":"R La Starza","year":"2007","unstructured":"La Starza R, Crescenzi B, Pierini V, Romoli S, Gorello P, Brandimarte L, et al. A common 93-kb duplicated DNA sequence at 1q21.2 in acute lymphoblastic leukemia and burkitt lymphoma. Cancer Genet Cytogenet. 2007;175:73\u20136.","journal-title":"Cancer Genet Cytogenet"},{"key":"2867_CR20","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.clbc.2016.12.009","volume":"17","author":"RA Denu","year":"2017","unstructured":"Denu RA, Burkard ME. synchronous bilateral breast cancer in a patient with nager syndrome. Clin Breast Cancer. 2017;17:e151-153.","journal-title":"Clin Breast Cancer"},{"key":"2867_CR21","first-page":"2139","volume":"36","author":"T Iguchi","year":"2016","unstructured":"Iguchi T, Komatsu H, Masuda T, Nambara S, Kidogami S, Ogawa Y, et al. Increased copy number of the gene encoding SF3B4 indicates poor prognosis in hepatocellular carcinoma. Anticancer Res. 2016;36:2139\u201344.","journal-title":"Anticancer Res"},{"key":"2867_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ebiom.2018.10.067","volume":"38","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li W, Pang Y, Zhou Z, Liu S, Cheng K, et al. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma. EBioMedicine. 2018;38:57\u201368.","journal-title":"EBioMedicine"},{"key":"2867_CR23","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.21873\/anticanres.14160","volume":"40","author":"J Lee","year":"2020","unstructured":"Lee J, Seo G, Hur W, Yoon SK, Nam SW, Lee JH. SRSF3 depletion leads to an increase in SF3B4 expression in SNU-368 HCC cells. Anticancer Res. 2020;40:2033\u201342.","journal-title":"Anticancer Res"},{"key":"2867_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13238-021-00856-5","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang H, Beutler B, Zhang D. Emerging roles of spliceosome in cancer and immunity. Protein Cell. 2022;13:559\u201379.","journal-title":"Protein Cell"},{"key":"2867_CR25","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s43018-021-00309-2","volume":"2","author":"M Foronda","year":"2021","unstructured":"Foronda M. RNA splicing meets anti-tumor immunity. Nat Cancer. 2021;2:1287.","journal-title":"Nat Cancer"},{"key":"2867_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1189\/jlb.5HI0214-074R","volume":"96","author":"H Janols","year":"2014","unstructured":"Janols H, Bergenfelz C, Allaoui R, Larsson AM, Ryden L, Bjornsson S, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol. 2014;96:685\u201393.","journal-title":"J Leukoc Biol"},{"key":"2867_CR27","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783\u201397.","journal-title":"J Immunol"},{"key":"2867_CR28","doi-asserted-by":"crossref","unstructured":"Jiang H, Zhang S, Song T, Guan X, Zhang R, Chen X. Trichostatin a protects dendritic cells against oxygen-glucose deprivation via the SRSF3\/PKM2\/Glycolytic pathway. Front Pharmacol. 2018;9:612.","DOI":"10.3389\/fphar.2018.00612"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02867-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:03:00Z","timestamp":1698631380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02867-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02867-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments performed in this study were conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of the Ajou University Hospital, Suwon, South Korea (AJRIB-BMR-KSP-18-397, AJIRB-BMR-KSP-18-299, AJOUIRB-EX-2022-389, and AJOUIRB-EX-2023-368). The requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}